CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Casgevy, a sickle cell treatment developed by Vertex and CRISPR Therapeutics, became the first CRISPR therapy approved by the US Food and Drug Administration (FDA) in December 2023. With AWS on ...

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum ...

Journavx should have huge commercial potential as a non-opioid painkiller. Meanwhile, Casgevy should also pick up momentum in treating sickle cell disease and transfusion-dependent beta-thalassemia.

It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire all outstanding shares of 2seventy bio for $5, valuing the deal at ~$286m. 2seventy bio, a Cambridge-based biotech ...

Try Now>> See the top stocks recommended by analysts >> Re CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.